HLB bioStep and KIT Sign MOU to Boost Preclinical Research with Primate Studies

(From left) HLB bioStep CEO Baek Sung-jin and KIT President Heo Jeong-du after signing the MOU for preclinical research cooperation. (Credit: HLB bioStep)

 

HLB bioStep signed an MOU with the Korea Institute of Toxicology (KIT) on April 28 to collaborate on preclinical trials, particularly involving primate studies. The agreement includes cooperation on technology exchange, test method development, facility sharing, and researcher training. Both parties aim to enhance bio-sample analysis and imaging-based testing, while also providing integrated testing services to meet client needs. The partnership is viewed as a model of public-private collaboration in Korea’s non-clinical research sector.

Read more: https://www.ittimes.com/news/articleView.html?idxno=72774

HLB BioStep, KIT Sign MOU to Boost Preclinical Research - IT타임스